TEL AVIV, June 6 (Reuters) - Israel’s Mazor Robotics MZOR.TA received approval from the U.S. Food and Drug Administration for the next generation of its spinal robotic surgical guidance system.
The Renaissance robot will extend the ability of surgeons to perform a wide range of procedures, including complex spine surgeries, Mazor said on Monday.
The company said it would begin sales immediately and would be able to raise the sales price for the robot.
Mazor’s previous systems for spine surgery, SpineAssist, was used in over 2,000 spinal surgeries worldwide, placing more than 12,000 implants.
Renaissance has a new design and human interface, as well as next-generation hardware and software. It also serves as a platform that will support future clinical applications, such as robotic-guided cranial surgeries.
Mazor’s shares were up 6.6 percent to 8.59 shekels in morning trade in Tel Aviv.
$1 = 3.38 shekels Reporting by Tova Cohen; Editing by Erica Billingham